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PPARg in Monocytes: Minireview
Less Pain, Any Gain?
optimal activation of the heterodimer requires both li-
gands, at least in the context of transcription assays
(Kliewer et al., 1992). Of course, RXR also serves as a
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to act selectively on the PPARg/RXR heterodimer.
Although the expression of PPARg in leukemic cells of
the myeloid lineage was described earlier, no biologicalIntroduction
function for this receptor in these cells has been de-As the population of the U.S. and other industrial coun-
scribed. In the past few months, four papers have pre-tries ages and gets fatter, there is a more urgent need
sented data suggesting that ligand activation of thisto understand the molecular basis of obesity and those
receptor powerfully regulates several aspects of mono-common and serious medical conditions clearly associ-
cyte biology in ways that offer potential therapeuticated with obesity: type II diabetes and cardiovascular
promise and potential worries about side effects.disease. The cloning and identification of PPARg as a
PPARg and Inflammationnuclear receptor that can regulate important facets of
Monocytes and macrophages are involved in inflamma-energy balance has offered new opportunities to under-
tory action through theelaboration of multiple moleculesstand and manipulate several key metabolic processes.
including nitric oxide (NO) and inflammatory cytokinesLigand activation of PPARg in cultured fibroblasts or
such as TNFa and IL-1. The first paper of this seriespreadipocytes stimulates adipose cell differentiation, in-
(Ricote et al., 1998) reports that PPARg mRNA is ex-cluding the cessation of cell growth (Spiegelman and
pressed at higher levels in peritoneal macrophages elic-Flier, 1996, and references therein). While adipose differ-
ited with thioglycollate than in monocytes obtained fromentiation is also increased by PPARg ligands in vivo,
the bone marrow. Ordinarily, when these peritonealthey do not necessarily cause a great increase in total
macrophages are treated with interferon g, they respondadipose mass (obesity). Recognition that PPARg is the
with an increase in the inducible form of nitric oxidereceptor for the antidiabetic thiazolidinedione (TZD)
synthase (iNOS) and NO, as well as the secretion ofdrugs, such as troglitazone (Rezulin), linked this receptor
other inflammatory products such as gelatinase B (Gelto glucose homeostasis in rodents and humans (Forman
B). Ricote et al. report that when these cells are treatedet al., 1995; Kliewer et al., 1995). It is estimated that
simultaneously with either of two different ligands for730,000 Americans currently take this drug to improve
PPARg, 15d-PGJ2 or very high concentrations (100 mM)insulin action in diabetes and advanced clinical trials
of the TZD BRL49653, the production of iNOS, NO, andare currently underway to assess its activity in other
Gel B is reduced. Analysis of the promoters of iNOS
insulin-resistant states such as polycystic ovarian syn-
and Gel B have revealed binding sites for AP-1, NF-kB,
drome. In addition, clinical trials are underway to assess
and STAT1. Using isolated multimerized sites, a TZD-
the ability of TZDs to prevent diabetes and to regulate
dependent repression of transcription through all of
cell growth in cancers of the adipogenic lineage (liposar- these elements was observed.
coma) and other, more common cancers as well. A related study was also performed in human mono-
Although adipose tissue has been recognized as a cytes by Jiang et al. (1998). It is well known that exposure
principal site of expression of PPARg, it is expressed of monocytes to lipopolysaccharide (LPS) or to tumor
at lower levels in many other tissues and cell types and promoters such as PMA potently and rapidly induce
may very well play important roles in nonadipose sites. inflammatory cytokines such as TNFa, IL-6, and IL-1B.
The ability to study PPARg in different biological con- In this study, a very wide range of ligands, including a
texts is enhanced by the availability of several classes TZD (troglitazone), 15d-PGJ2,and certain NSAIDs strongly
of ligands. The TZDs are synthetic compounds that are inhibited cytokine production. The NSAIDs are of partic-
very specific agonists for PPARg (KD 5 30±700 nM) ular interest because it has been observed that certain
(Forman et al., 1995; Lehmann et al., 1995). 15-deoxyD12-14 compounds such as indomethacin and ibuprofen can
prostglandin J2 (15d-PGJ2) is a natural ligand that has have incremental anti-inflammatory actions at concen-
lower affinity for PPARg than the TZDs (KD 5 2 mM) and trations far above the levels needed to inhibit cyclooxy-
may not be as selective for this receptor (Forman et al., genase. Interestingly, these PPARg agonists suppressed
1995; Kliewer et al., 1995; Brun et al., 1996). Certain cytokine production elevated by PMA, but not by LPS.
polyunsaturated fatty acids such as linoleic acid also This suggests a clear-cut specificity in the inhibitory
bind to and activate PPARg, though the affinity here is mechanisms mediated by PPARg. Taken together, these
in the 10±20 mM range (Kliewer et al., 1997). In addition, two papers demonstrate that ligands for PPARg were
certain nonsteroidal anti-inflammatory drugs (NSAIDs) effective in reducing levels of inflammatory cytokines,
like ibuprofen can activate this receptor (Lehmann et as well as downstream markers of inflammation such
al., 1997). Although the KD for PPARg is quite high (100 as NO elaborated by monocytic cells. It will be important
mM), this receptor may participate in some actions of for the future to try to develop a greater mechanistic
the NSAIDs that cannot be ascribed to inhibition of understanding of how PPARg can suppress this broad
cyclooxygenase. Finally, PPARg functions as an obli- range of inflammatory functions. In particular, the diver-
gence in efficacy of PPARg ligands depending on thegate heterodimer with the retinoid X receptor (RXR) and
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particular agents inducing the monocytes is of consider- induction of CD36 by PPARg opens up the interesting
possibility of a positive-feedback loop.able interest.
PPARg and Foam Cell Conversion Is PPARg the Major Target?
One significant difficulty in interpreting most of the ex-One of the earliest steps in the formation of atheroscle-
rotic plaques in the walls of large blood vessels is the periments discussed above is that they have employed
ligands, such as 15d-PGJ2, that may not be very selec-conversion of macrophages to cholesterol-engorged
foam cells (reviewed in Steinberg et al., 1989). These tive for PPARg. When more selective ligands, such as
BRL49653, were employed, extremely high concentra-are cells that have internalized lipids and stored them
as cytoplasmic droplets, which gives the cells their char- tions were necessary to achieve the results described.
The suppression of NO in macrophages by 15d-PGJ2,acteristic foamy appearance in light microscopy. One
way to generate such cells is to expose monocytes to occurs in a concentration range (1±10 mM) that is consis-
tent with its KD for PPARg. However, other ligands foroxidized LDL (oxLDL) particles. The internalization of
the oxLDL does not occur by the LDL receptor, but PPARg such as BRL49653 required 50 mM toaccomplish
this, a concentration approximately 1000-fold above therather through the so-called scavenger receptors, such
as SR-A, CD36, and others. It is important to note that KD for this receptor. Similarly, the suppression of iNOS
requires much greaterconcentrations of BRL49653 thanfoam cell formation is not exclusively associated with
atherosclerosis; such cells can also be found at other 15d-PGJ2, despite the fact that BRL49653 has a much
higher affinity for the receptor. While cellular metabolismsites in certain physiological or pathological states and
the stored lipid can be predominantly triglyceride. of these compounds may affect their relative efficacy
as ligands, the TZDs influence other PPARg-mediatedTwo new papers in this issue of Cell suggest that
PPARg is involved in the development of monocytes processes such as adipose differentiation and insulin
sensitivity in concentration ranges generally consistentalong the macrophage lineage, in particular in the con-
version of monocytes to foam cells. In the first of these with their affinity for this receptor (Forman et al., 1995;
Kawai et al., 1997). In terms of cytokine production bystudies (Tontonoz et al., 1998), activation of HL60 mono-
cytic leukemia cells with the combination of the PPARg monocytes, 15d-PGJ2 was also more potent and effica-
cious than other PPARg ligands such as TZDs, leadingagonist 15d-PGJ2 and the RXR ligand LG268 causes
induction of the macrophage markers CD11b and CD18. Jiang et al. (1998) to conclude that the activation of
additional pathways may also be involved in these re-As part of this differentiative response, more PPARg is
induced. Of interest, PPARg could also be induced by sponses. With regard to monocyte maturation and foam
cell conversion, once again many of these effects areexposure of monocytic cells to oxLDL, but not to the
parent LDL particle, suggesting that some component most effectively brought about by the less specific 15d-
PGJ2, particularly when used in combination with anof theoxidized LDL isable to induce PPARg.Conversely,
exposure of cells to 15d-PGJ2 or troglitazone in combi- RXR agonist. Of course, simultaneous activation of RXR
may elicit more activity from the PPARg/RXR hetero-nation with LG268 increases the binding of oxLDL but
not LDL. This study further showed that this increased dimer, but it is important to note that adipogenesis and
insulin sensitization, the most intensively studied activi-oxLDL binding occurs through greater expression of
CD36 but not two of the other oxLDL receptors, SRA- ties of PPARg, do not require costimulation of RXR
(Spiegelman and Flier, 1996). This opens the possibilityType I or Type II. This induction of the CD36 activity
required the combination of a PPARg agonist (troglita- that alternative or additional pathways are involved in
induction of CD36 (oxLDL receptor) and other compo-zone) and an RXR ligand; neither alone could carry out
this function. nents of the foam cell conversion. 15d-PGJ2, unlike the
TZDs, is also an activator of PPARa and could also haveThe second paper of this series (Nagy et al., 1998)
investigates the nature of the components of oxLDL that cell surface receptors, as do many prostanoids. Clearly,
more study of these systems with highly selective li-can activate PPARg. This was done by screening known
oxidized lipid components of these particles in a tran- gands, including some recently developed outside the
TZD class (T. Willson, personal communication), shouldscription assay using the ligand-binding domain of
PPARg fused to the DNA-binding domain of Gal4. These clarify these points.
Implications for Human Therapyexperiments pointed to 9- and 13-hydroxyoctadenoic
acid (HODE), oxidation products of linoleic acid. These These papers represent intriguing data obtained from
isolatedmonocytic cells. If the implications of thepaperscompounds themselves can mimic oxLDL in inducing
monocyte maturation and CD36 expression, especially are realized in vivo, this may represent both good and
bad news. Approximately 730,000 Americans now takewhen combined with an RXR agonist. Finally, it is shown
that 9-HODE and 13-HODE bind directly to PPARg and a drug (troglitazone) known to function as a PPARg li-
gand, so these are important issues. If a PPARg ligandcan displace a TZD (BRL49653) with a Ki of 10±20 mM.
One question not approached directly in these studies can effectively suppress monocytic activation, NO pro-
duction, and the secretion of cytokines, this suggestsis whether the oxidation of linoleic acid affects its ability
to serve as a ligand for PPARg. Since it has previously that TZDs or other ligands could have a major impact
on inflammatory disease. Since millions of people sufferbeen shown that linoleic acid binds to PPARg with a KD
of z10 mM, it is not clear whether the HODEs have from conditions of chronic inflammation, such as rheu-
matoid arthritis and inflammatory bowel disease, newbetter affinity than the parent compound. Of course, the
oxidation of the LDL particle could still serve as a spe- orally active drugs to control inflammation would be
welcomed. This is particularly true because high dosescific trigger by providing a means of delivering this rela-
tively low-affinity activator to cells expressing CD36. The and prolonged application of NSAIDs are often difficult
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Koble, C.S., Devchand, P., Wahli, W., Willson, T.M., Lenhard, J.M.,for patients to tolerate. Despite the recent announce-
and Lehmann, J.M. (1997). Proc.Natl. Acad. Sci. USA 94, 4318±4323.ment that troglitazone may cause a rare, idiosyncratic
Lehmann, J.M., Morre, L.B., Smith-Oliver, T.A., Wilkison, W.O., Will-liver toxicity in some humans (Food and Drug Adminis-
son, T.M., and Kliewer, S.A. (1995). J. Biol. Chem. 270, 12953±12956.tration, 1997), most patients tolerate this drug with few,
Lehmann, J.M., Lenhard, J.M., Liver, B.B., Ringold, G.M., andif any, side effects. To date, there have been no studies
Kliewer, S.A. (1997). J. Biol. Chem. 272, 3406±3410.
in animals or humans concerning the effects of a specific
Minamikawa, J., Yamauchi, M., Inoue, D., and Koshiyama, H. (1998).agonist for PPARg on inflammation.
J. Clinic. Endo. Met. 83, 1041.
The implications of the monocyte-foam cell papers
Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H., and Evans, R.M.
are not so pleasant to contemplate. The TZD drugs are (1998). Cell 93, this issue, 229±240.
used to treat patients with noninsulin-dependent diabe- Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. (1998).
tes mellitus, a disease that carries a very large cardio- Nature 391, 79±82.
vascular risk. When one considers that the vast majority Spiegelman, B.M., and Flier, J.S. (1996). Cell 87, 377±389.
of these patients in the U.S. and Europe are also obese, Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Wit-
a condition that adds a second, independent cardiovas- zum, J.L. (1989). N. Engl. J. Med. 320, 915±924.
cular risk, any acceleration of atherogenesis promoted Tontonoz, P., Nagy, L., Alvarez, J.G.A., Thomazy, V.A., and Evans,
by these drugs would clearly be unacceptable. What do R.M. (1998). Cell 93, this issue, 241±252.
the clinical data show to date? All of the antidiabetic TZD
drugs lower blood lipids in both rodents and humans
and, hence, would be expected to reduce cardiovascu-
lar risk. Preliminary data in humans taking troglitazone
has shown, as expected, a reduction in atherosclerosis
(Minamikawa et al., 1998). There are several possible
ways to reconcile these data. First, given that the mono-
cyte to foam cell conversion shown in Tontonoz et al.
(1998) requires simultaneous application of PPARg li-
gands and RXR agonists, the TZD drugs applied as a
monotherapy may not achieve either the level of activa-
tion of PPARg in vivo or activation of additional path-
ways (as discussed above) necessary for the foam cell
reaction. Secondly, foam cell conversion is a highly visi-
ble component of atherosclerotic lesions but it is not
clear that foam cell generation per se would necessarily
promote clinically significant atherogenesis in the ab-
sence of other pathological processes occurring within
blood vessels. Finally, it is conceivable that TZD activa-
tion of PPARg may induce expression of scavenger re-
ceptors such as CD36 in other cells besides macro-
phages. This receptor is highly expressed in fat, for
example, and its up-regulation by TZDs in this tissue
could, in fact, provide a relatively benign sink for poten-
tially deleterious oxLDL. This is an exciting possibility
that should be investigated. The application of selective
PPARg agonists to animal models of inflammation and
atherosclerosis should shed light on the ability of this
receptor to modulate these important biological effects.
Selective Reading
Brun, R.P., Tontonoz, P., Forman, B.M., Ellis, R., Chen, J., Evans,
R.M., and Spiegelman, B.M. (1996). Genes Dev. 10, 974±984.
Food and Drug Administration (1997). FDA Talk paper (Washington,
D.C.: U. S. Department of Health and Human Services), Dec. 1.
Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M.,
and Evans, R.M. (1995). Cell 83, 803±812.
Jiang, C., Ting, A.T., and Seed, B. (1998). Nature 391, 82±86.
Kawai, K., Kawasaki-Tokui, Y., Odaka, T., Tsuruta, F., Kuzui, M.,
Iwabuchi, H., Nakamura, T., Kinoshita, T., Ikeda, T., Yoshioka, T., et
al. (1997). Azneimittelforschung 47, 356±368.
Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A., and Evans,
R.M. (1992). Nature 358, 771±774.
Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris, D.C.,
and Lehmann, J.M. (1995). Cell 83, 813±819.
Kliewer, S.A., Sundseth, S.S., Jones, S.A., Brown, P.J., Wisely, G.B.,
